All In Biotech

Drug Trial Radar · NCT00857987

Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections.

Randomized , Placebo-controlled, Clinical Trial of Efficacy and Safety Evaluation of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improving the Signs and Symptoms of Infections of Way Upper (URI)

Last checked: Nov 19, 2026Latest source record: Jan 28, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

174

Planned (sponsor's estimate)

Start

Apr 2010

Primary completion

Oct 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Azidus BrasilIndustry
Sponsor type
Industry
First posted
Mar 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the improvement of the common cold with the use of medication

Conditions

  • Upper Airway Infections

Interventions

  • EMS ExpectorantDrug

    Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.

  • PlaceboOther

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - Decrease in nasal secretion - Decrease in sneezing - Reduction of edema of the nasal mucosa - Decreased frequency of cough - Decrease the frequency of dyspnea - Reduction of nasal obstructionTime frame: Screening (Day 0); Return to 1 day; Return to 3 days (+/-1); Return of 7 days (+ / -2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • LAL Clinica Pesquisa e Desenvolvimento Ltda

    Valinhos, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.